The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis

• Published in: Critical care medicine Vol. 29; no. 1; p. 13
• Main Authors: Opal, S M, Palardy, J E, Parejo, N A, Creasey, A A
• Format: Journal Article
• Language: English
• Published: United States 01.01.2001
• Subjects: Animals; Anticoagulants - therapeutic use; Cytokines - blood; Endotoxins - blood; Factor Xa Inhibitors; Lipoproteins - therapeutic use; Mice; Mice, Inbred BALB C; Peritonitis - drug therapy; Peritonitis - immunology; Peritonitis - mortality; Random Allocation; Recombinant Proteins - therapeutic use; Shock, Septic - drug therapy; Shock, Septic - immunology; Shock, Septic - mortality; Staphylococcus; Statistics, Nonparametric; Superantigens; Survival Rate
• ISSN: 0090-3493
• DOI: 10.1097/00003246-200101000-00003

To study recombinant human tissue factor pathway inhibitor (rhTFPI) in a superantigen-induced shock model and in a cecal ligation and puncture (CLP) model of peritonitis in mice. Prospective, randomized, experimental study. An experimental animal research laboratory. Eighty BALB/c mice for the superantigen model, and 56 BALB/c mice for the CLP model. In the superantigen-induced shock model, animals received rhTFPI (350 mg/kg) subcutaneously every 12 hrs (n = 30) or saline control (n = 30) for 60 hrs after staphylococcal enterotoxin B (SEB; 10 microg iv) and a sublethal dose of E. coli 0111:B4 lipopolysaccharide (LPS; 75 microg ip). Control groups received SEB alone (n = 10) and LPS alone (n = 10). In the CLP model, rhTFPI or saline was given every 8 hrs for 48 hrs by using a 21-gauge needle (n = 9) or 23-gauge needle (n = 14) for CLP. A sham surgery control group (n = 10) was also included. There was 0% mortality in the SEB and LPS control groups. The mortality rate was 64% in the saline control group that received both SEB and LPS (19 of 30), whereas the rhTFPI- treated animals had a mortality rate of 20% (6 of 30; p < .01). The rhTFPI-treated group had significantly lower interleukin-6 levels (61.8 +/- 41 pg/mL vs. 285 +/- 63 pg/mL; p < .05) than the control group but no differences in tumor necrosis factor-alpha or interferon-gamma levels. In the CLP experiment, rhTFPI-treated animals did not have any survival advantage over the control group after the large-bore (21-gauge) needle puncture. The rhTFPI group had significantly improved 7-day mortality rate after CLP with the small-bore needle (23-gauge; 21.4% [rhTFPI] vs. 71.4% [control], p < .01). Plasma LPS, interleukin-6, interferon-gamma, and tumor necrosis factor-alpha levels were unchanged by rhTFPI treatment, but significantly reduced LPS (p = .006) and IFNgamma (p = .001) levels were found in the peritoneal fluid. Tissue factor pathway inhibitor significantly improves the mortality rate in models of superantigen-induced shock and polymicrobial intra-abdominal infection, supporting its potential use in clinical trials for septic shock.